Xeomin / Bocouture

Record type

Source-linked family profile

Recorded maker

Merz Aesthetics

Classification

Neuromodulator

Material identity

incobotulinumtoxinA

Snapshot date

14 August 2026

Manufacturer and category are catalogue fields. They are not, by themselves, a regulatory classification or verification of the exact marketed presentation.

Names and markets

Aliases in this profile

• Xeomin

  United States brand name in the attached source

• Bocouture

  United Kingdom brand name in the attached source

Alias grouping supports discovery. It does not claim that regional products, labels, units, formulations, or authorised uses are interchangeable.

Product names and regulatory context do not travel automatically between countries. Each row below is limited to its named source market.

1. Manufacturer

   1. Xeomin Aesthetic official site

   Merz Aesthetics · United States

   Open source ↗

   Supports: Xeomin brand identity and United States manufacturer context.

2. Approved label

   2. BOCOUTURE 50 units — Summary of Product Characteristics

   electronic Medicines Compendium · United Kingdom

   Open source ↗

   Supports: The UK BOCOUTURE identity, Merz Aesthetics UK company context, presentation, and botulinum-toxin-type-A wording.

3. Approved label

   3. XEOMIN — current United States drug label

   U.S. National Library of Medicine (DailyMed) · United States

   Open source ↗

   Supports: The current US XEOMIN identity, Merz packager context, and incobotulinumtoxinA naming.

1. 1

   Market-scoped names

   XEOMIN and BOCOUTURE are separately documented Merz brand identities used in the US and UK source contexts.

   Scope: The atlas groups the names for discovery and does not assert presentation or label equivalence.

   Evidence: BOCOUTURE 50 units — Summary of Product CharacteristicsEvidence: XEOMIN — current United States drug label
2. 2

   Material / active name

   The US source uses incobotulinumtoxinA; the UK source uses botulinum toxin type A wording.

   Scope: Source terminology only; no dose or unit conversion is provided.

   Evidence: BOCOUTURE 50 units — Summary of Product CharacteristicsEvidence: XEOMIN — current United States drug label

Use boundary

What this record does not establish

• Regulatory statusOnly within a source's named jurisdiction; family-profile review does not establish status elsewhere.
• Authenticity or supply chainA catalogue name cannot authenticate an individual box, lot, or seller.
• Clinical suitabilityNo product selection, patient assessment, dose, protocol, or injection technique is provided.
• Availability or equivalenceNames, formulations, units, and presentations can vary by market and over time.